Oncology Medical Billing Services

Verify coverage and authorisation before the drug is ordered, not before it is given. Once a practice purchases an expensive agent for a specific patient, the cash is already committed. Confirming benefits, approval, and remaining cycles at the ordering stage is the only reliable protection. We build that check into the treatment planning step rather than the billing step.

Using the administration hierarchy. One service is the initial administration, others are sequential or concurrent depending on whether they overlapped. Billing them as equal separate charges both underpays and invites review. The hierarchy is built from documented start and stop times for each agent, which is why those times matter far more in oncology than elsewhere.

Only if it is recorded at the chair. Single-use vials frequently contain more than the calculated dose, and the discarded remainder can be billable when documented properly. Reconstructing it afterwards does not hold up. Recording administered and discarded amounts at the point of care converts a routine loss into recoverable revenue on almost every infusion day.

The existing authorisation usually stops applying. Approvals are granted for a specific regimen and a set number of cycles, so a change in agent or schedule typically needs a fresh request. Continuing on the old approval leads to a denial on a very expensive claim. We flag regimen changes as an authorisation trigger before the next treatment is given.

Yes, and at treatment planning rather than after a balance appears. Manufacturer and foundation programmes can cover substantial patient responsibility, but many require enrolment before treatment starts. Patients facing large balances often simply cannot pay them, so screening early protects both the patient and your collections. We build the screen into the pre-treatment workflow.

Because attention concentrates on the primary agent. Growth factors, antiemetics, hydration, and injections given alongside chemotherapy are separately billable, and they are easy to overlook on a busy infusion day. We reconcile the full treatment log rather than just the chemotherapy order, which routinely recovers charges that were performed and documented but never claimed.

Device placement is a separate procedure from the infusion work, and accessing an existing port is handled differently again depending on what else happened that day. Practices often bundle these into the treatment charge and lose the value. We review the day's documentation for access and device work as part of standard reconciliation.

Usually a mismatch between billed units and the payer's expected dosing, or a rate applied below your contract. Because drug lines are so large, even a small percentage gap is significant. Posting line by line against loaded contract rates exposes it. We appeal drug underpayments specifically, since they are frequently absorbed silently into contractual adjustments.

Differently from infused agents, because they usually run through a pharmacy benefit rather than the medical benefit. That changes who authorises, who dispenses, and who gets paid. Patients can face substantial cost sharing. We verify which benefit applies before the prescription is written, so nobody discovers the problem when the patient reaches the pharmacy.

Drug margin reported separately from service revenue. A practice can look profitable overall while losing money on specific regimens, and blended reporting hides that completely. You should see acquisition cost against reimbursement by agent. That view tells you which regimens are financially sustainable, which is a conversation most practices cannot currently have.